Background/Aims: Scarce data exist on the effects of soy isoflavones (IF) on bone during peripuberty, a known ‘window of opportunity’ for bone consolidation. Our aim was to determine the skeletal, reproductive, and serum estradiol (E2)/estrogenic activity response of consuming naturally-occurring soy protein-associated IF during peripuberty. Methods: Weanling (∼3 weeks old), female rats were placed on one of four nutritionally-complete dietary regimens in which protein (200 g/kg diet) was provided as casein or soy protein isolates containing either 0.11 (Low IF), 2.16 (Med IF), or 3.95 (High IF) mg total aglycone isoflavones/g protein for 8 weeks, during which body weights and estrus cycling were recorded. Results: Bone growth and density were unaffected by soy intake while the reproductive tissues showed a slight response (greater uterine weights of the Med and High IF groups). Despite suppression of E2 concentrations in the High IF group, total circulating estrogenic activity was unaltered. Moreover, in the High IF group, E2 was significantly depressed compared with bioassayable estrogenic activity, suggesting negative feedback inhibition of E2 by the elevated circulating levels of IF. Conclusions: This suppression in E2 with maintenance of total serum estrogenicity in the High IF group may explain the lack of effect observed in the skeletal tissues.

Keywords:
Soy, Bone, Growth, Estrogenic activity, Skeletal effects, Adolescence
This content is only available via PDF.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.